Australia markets open in 7 hours

Exicure, Inc. (XCUR)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.2200-0.2500 (-10.12%)
As of 12:56PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.4700
Open2.4100
Bid2.2300 x 800
Ask2.2500 x 800
Day's range2.2000 - 2.4800
52-week range1.4900 - 43.5000
Volume161,682
Avg. volume667,770
Market cap11.016M
Beta (5Y monthly)1.27
PE ratio (TTM)N/A
EPS (TTM)-0.6190
Earnings date10 Aug 2022 - 15 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.50
  • Business Wire

    Exicure, Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement

    CHICAGO, July 20, 2022--Exicure, Inc. (Nasdaq: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that on July 19, 2022, it received a letter from the Office of General Counsel of The Nasdaq Stock Market LLC informing it that Nasdaq has confirmed that the Company has regained compliance with the $1.00 per share minimum

  • Business Wire

    Exicure, Inc. Announces Receipt of Nasdaq Notice of Non-compliance and Implementation of One-for-Thirty Reverse Stock Split

    CHICAGO, June 29, 2022--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that, following the implementation of a one-for-thirty reverse stock split at 5:00 p.m. EDT today, the Company’s common stock will begin trading on a split-adjusted basis on Nasdaq effective with the open of business tomor

  • Business Wire

    Exicure, Inc. Announces Adjournment of Annual Meeting of Stockholders

    CHICAGO, May 27, 2022--Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that the Company’s Annual Meeting of Stockholders (the "Annual Meeting") held in virtual format on Friday, May 27, 2022 at 1:00 p.m. Central Time, was convened and adjourned until June 10, 2022 at 1:00 p.m. Central Time wit